solid tumor
Conditions
Interventions
observation group:None
Sponsors
The Second Affiliated Hospital of Hunan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Confirmed by histopathology as solid tumor [lung cancer, colorectal cancer, gynecological tumor (cervical cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, breast cancer), liver cancer, brain glioma], etc.; 2. Age =18 years old at diagnosis; 3. Bevacizumab was used in previous treatment; 4. Include at least one complete treatment cycle with bevacizumab; 5. Cases are traceable. 6. Have adequate bone marrow function, ANC=1.5×109/L, platelets =100×109/L, hemoglobin =9.0g/dL. 7. Have adequate liver and renal function, serum total bilirubin =1.5×ULN and < 2mg/dL, ALT and AST=2.5×ULN, or =5×ULN during liver metastasis, creatinine clearance =50 mL /min, serum potassium and magnesium within the normal range of laboratory values.
Exclusion criteria
Exclusion criteria: 1. Serious underlying diseases such as combined infection, severe anemia, and severe cardiovascular disease, acute myocardial infarction, acute coronary syndrome (including unstable angina, coronary artery bypass surgery, coronary angioplasty, or stenting) occurring within the first 6 months of the treatment cycle with bevacizumab, congestive heart failure requiring treatment (New York Heart Association classification = 2), clinically significant arrhythmias (including uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia) occurring within the first 1 year of the treatment cycle, and thromboembolism or cerebrovascular events occurring within the first 1 year of the treatment cycle. For example, transient ischemic attack, cerebrovascular accident, deep vein thrombosis or pulmonary embolism with hemodynamic significance (i.e. large or sub large area). e. Three consecutive electrocardiograms with an average QTcF interval of = 480 ms or a history of QT prolongation syndrome, congenital LQTS; 2. Incomplete clinical data and lack of necessary data; 3. Participated in clinical trials of other anti-VEGF /VEGFR macromolecular drugs before using bevacizumab: Rituximab injection, Apatinib, Acitinib, Sorafenib, Linifanib, vandetanib, cabozantinib, Regorafenib, Pazopanib, Sunitinib, Lenvatinib, Tivozanib, Brinib, Nintedanib, Motesanib, Sildenib, Compaucept ophthalmic injection, Leizumab injection, Fuquitinib; 4. According to the researchers' judgment, there are other circumstances that should not be included
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The use of bevacizumab and combination therapy regimen;Adverse event; | — |
Countries
China
Contacts
Public ContactCao Wen
The Second Affiliated Hospital of Hunan University of Chinese Medicine
Outcome results
None listed